SIP
NKTR icon

Stoneridge Investment Partners’s Nektar Therapeutics NKTR Stock Holding History

Stoneridge Investment Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,829
Closed -$635K – 128
2020
Q2 		$635K Sell
1,829
-394
-18% -$123K 0.27% 86
2020
Q1 		$595K Hold
2,223
– – 0.27% 79
2019
Q4 		$720K Sell
2,223
-53
-2% -$15.4K 0.24% 102
2019
Q3 		$622K Sell
2,276
-149
-6% -$54.6K 0.23% 104
2019
Q2 		$1.29M Buy
+2,425
New +$1.22M 0.46% 74
2017
Q4 		– Sell
-720
Closed -$259K – 247
2017
Q3 		$259K Sell
720
-2,804
-80% -$877K 0.04% 191
2017
Q2 		$1.03M Buy
+3,524
New +$1.02M 0.15% 113
2017
Q1 		– Sell
-3,156
Closed -$581K – 337
2016
Q4 		$581K Buy
+3,156
New +$642K 0.08% 215
2014
Q1 		– Sell
-6,506
Closed -$1.11M – 219
2013
Q4 		$1.11M Buy
6,506
+1,203
+23% +$194K 0.21% 85
2013
Q3 		$831K Buy
5,303
+1,080
+26% +$200K 0.18% 95
2013
Q2 		$732K Buy
+4,223
New +$648K 0.17% 91

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Stoneridge Investment Partners's NKTR Position: Q3 2020 in Review

Stoneridge Investment Partners sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 1,829 shares — an estimated $635K sold.

Stoneridge Investment Partners first reported a position in NKTR in Q2 2013 and held it in 11 quarters. The position peaked at $1.29M in Q2 2019. 248 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Stoneridge Investment Partners reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Stoneridge Investment Partners sold 1,829 Nektar Therapeutics shares in Q3 2020, an estimated $635K.
  • Stoneridge Investment Partners first reported a position in Nektar Therapeutics in Q2 2013 and held it in 11 quarters.
  • Stoneridge Investment Partners's Nektar Therapeutics position peaked at $1.29M in Q2 2019.
  • 248 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Stoneridge Investment Partners's 13F filing for Q3 2020, filed 28 Oct 2020.